Human IFN-alpha / beta R1 Alexa Fluor® 350-conjugated Antibody
Human IFN-alpha / beta R1 Alexa Fluor® 350-conjugated Antibody Summary
Gly26-Lys436
Accession # P17181
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, 2 to 8 °C as supplied.
Background: IFN-alpha/beta R1
Interferon‑alpha/beta receptor 1 (IFN‑ alpha / beta R1), also known as IFNAR1, is a 100‑130 kDa member of the class II cytokine receptor family of proteins. These proteins form heterodimeric receptor complexes that mediate class II cytokine signals. Subunits of the different receptor complexes are shared and serve multiple functions (1). IFN‑ alpha / beta R1, in association with IFN‑ alpha / beta R2, is required for propagating anti‑microbial signal transduction triggered by the type 1 interferons such as IFN‑ alpha and IFN‑ beta (2, 3). Mature human IFN‑ alpha / beta R1 consists of a 409 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 100 aa cytoplasmic domain (4). The ECD contains three tandem fibronectin type III repeats and is extensively glycosylated. Within the ECD, human IFN‑ alpha / beta R1 shares 47% and 50% aa identity with mouse and rat IFN‑ alpha / beta R1, respectively. Alternative splicing generates two additional isoforms that lack the transmembrane segment and either all or a portion of the cytoplasmic domain. IFN‑ alpha / beta R1 interacts very weakly or not at all with type 1 interferons and does not stably interact with IFN‑ alpha / beta R2. Ligands preferentially associate with IFN‑ alpha / beta R2, and this complex subsequently forms a stable ternary assembly with IFN‑ alpha / beta R1 (5‑7). IFN‑ alpha / beta R1 also associates with IFN‑ gamma R2 even in the absence of IFN‑ gamma stimulation (3). IFN‑ alpha / beta R1 activation depends on tyrosine phoshorylation as well as palmitoylation of its cytoplasmic domain (8, 9). Rapid down‑regulation of the receptor is accomplished by ligand‑dependent or ‑independent pathways (e.g. VEGF R signaling, TLR signaling, or cellular stress) which induce its serine phosphorylation, ubiquitination, and degradation (10‑13).
- Langer, J.A. et al. (2004) Cytokine Growth Factor Rev. 15:33.
- Hwang, S.Y. et al. (1995) Proc. Natl. Acad. Sci. USA 92:11284.
- Takaoka, A. et al. (2000) Science 288:2357.
- Uze, G. et al. (1990) Cell 60:225.
- Lamken, P. et al. (2004) J. Mol. Biol. 341:303.
- Arduini, R.M. et al. (1999) Prot. Sci. 8:1867.
- Kalie, E. et al. (2008) J. Biol. Chem. 283:32925.
- Platanias, L.C. (2005) Nat. Rev. Immunol. 5:375.
- Claudinon, J. et al. (2009) J. Biol. Chem. 284:24328.
- Zheng, H. et al. (2011) Blood 118:4003.
- Qian, J. et al. (2011) PLoS Pathogens 7:e1002065.
- Bhattacharya, S. et al. (2010) J. Biol. Chem. 285:2318.
- Bhattacharya, S. et al. (2011) J. Biol. Chem. 286:22069.
Product Datasheets
Product Specific Notices
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human IFN-alpha / beta R1 Alexa Fluor® 350-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human IFN-alpha / beta R1 Alexa Fluor® 350-conjugated Antibody and earn rewards!
Have you used Human IFN-alpha / beta R1 Alexa Fluor® 350-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image